Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011).
暂无分享,去创建一个
T. Akasaka | M. Hayashi | R. Nohara | H. Daida | K. Okumura | H. Iso | H. Shimokawa | M. Yamagishi | J. Sasaki | Yasuyuki Nakamura | K. Saku | S. Hokimoto | T. Sakamoto | K. Tsujita | H. Ogawa | H. Ishii | Keiji Tanaka | M. Ishihara | Teruo Inoue | K. Mizuno | S. Miyazaki | M. Kosuge | K. Kimura | Masaaki Ito | H. Tsutsui | Yoshihiko Saito | H. Takano | H. Sumida | M. Horii | Takahiro Hayashi | H. Adachi | Mashio Nakamura | M. Yoshimura | S. Kojima | S. Tani | K. Kanamasa | K. Nagao | M. Sakakibara | A. Iwata | T. Higuma | S. Abe | Tatsuya Suga | Yasuyuki Nakamura | Teruo Inoue
[1] M. Shoda,et al. Guidelines for Non-Pharmacotherapy of Cardiac Arrhythmias (JCS 2011). , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[2] J. McMurray,et al. Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.
[3] K. Swedberg,et al. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. , 2010, European heart journal.
[4] D. Grobbee,et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.
[5] S. Connolly,et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. , 2010, Journal of the American College of Cardiology.
[6] J. Gore,et al. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events. , 2010, European heart journal.
[7] H. Yagi,et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[8] C. White,et al. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin IIReceptor Blockers for Ischemic Heart Disease , 2009, Annals of Internal Medicine.
[9] J. Connell,et al. Aldosterone status associated with insulin resistance in patients with heart failure—data from the ALOFT study , 2009, Heart.
[10] Hakuo Takahashi,et al. Oral nicorandil to reduce cardiac death after coronary revascularization in hemodialysis patients: a randomized trial. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] Katsumi Miyauchi,et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin , 2009, Journal of the American College of Cardiology.
[12] N. Schneiderman,et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. , 2009, Journal of psychosomatic research.
[13] J. McMurray,et al. Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? , 2009, American heart journal.
[14] P. Sever,et al. Managing cardiovascular and renal risk: the potential of direct renin inhibition , 2009, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[15] Hae-Young Lee,et al. Cardio–renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program , 2009, Expert review of cardiovascular therapy.
[16] M. Hirai,et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[17] G. Bakris,et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.
[18] R. Holman,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.
[19] S. Kusachi,et al. Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction. , 2008, Circulation journal : official journal of the Japanese Circulation Society.
[20] D. Horstkotte,et al. Adaptive servoventilation improves cardiac function in patients with chronic heart failure and Cheyne–Stokes respiration , 2008, European journal of heart failure.
[21] S. Yano,et al. Comparison of sarpogrelate and ticlopidine in bare metal coronary stent implantation. , 2008, International journal of cardiology.
[22] S. Solomon,et al. Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure , 2008, Circulation. Heart failure.
[23] S. Yusuf,et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.
[24] D. Yuh,et al. Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data. , 2008, The Journal of thoracic and cardiovascular surgery.
[25] N. Hagiwara,et al. Long-Term Nitrate Use in Acute Myocardial Infarction (The Heart Institute of Japan, Department of Cardiology Nitrate Evaluation Program) , 2008, Cardiovascular Drugs and Therapy.
[26] O. Pedersen,et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.
[27] R. Nagai,et al. Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. , 2007, Circulation journal : official journal of the Japanese Circulation Society.
[28] A. Hirayama,et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials , 2007, The Lancet.
[29] Deepak L. Bhatt,et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.
[30] A. Skene,et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. , 2007, Journal of the American College of Cardiology.
[31] M. Pfeffer,et al. Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system , 2007, Journal of hypertension.
[32] Y. Matsuzawa,et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.
[33] C. Tei,et al. Long-term nitrate therapy after acute myocardial infarction does not improve or aggravate prognosis. , 2007, Circulation journal : official journal of the Japanese Circulation Society.
[34] L. Køber,et al. A systematic review: Effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction , 2007, European journal of heart failure.
[35] T. Kurata,et al. Prognostic value of the metabolic syndrome for long-term outcomes in patients undergoing percutaneous coronary intervention. , 2006, Circulation journal : official journal of the Japanese Circulation Society.
[36] Dan M. Roden,et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .
[37] S. Yusuf,et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.
[38] Nick Freemantle,et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. , 2006, European heart journal.
[39] G. Mancia,et al. Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. , 2006, European heart journal.
[40] M. Pfeffer,et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.
[41] W. Weaver,et al. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. , 2006, Journal of the American College of Cardiology.
[42] H. Shimomura,et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. , 2006, The American journal of cardiology.
[43] P. Steg,et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. , 2006, Archives of internal medicine.
[44] F. Dagenais,et al. Influence of time elapsed between myocardial infarction and coronary artery bypass grafting surgery on operative mortality. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[45] C. O'connor,et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. , 2005, Journal of the American College of Cardiology.
[46] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.
[47] A. Moss,et al. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). , 2005, The American journal of cardiology.
[48] M. Nobuyoshi,et al. Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study. , 2005, Circulation journal : official journal of the Japanese Circulation Society.
[49] X. Drouot,et al. Compliance with and effectiveness of adaptive servoventilation versus continuous positive airway pressure in the treatment of Cheyne-Stokes respiration in heart failure over a six month period , 2005, Heart.
[50] D. Tanné,et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. , 2005, Archives of internal medicine.
[51] S. Hosoda,et al. Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery. , 2005, Circulation journal : official journal of the Japanese Circulation Society.
[52] C. Rochitte,et al. Late coronary artery recanalization effects on left ventricular remodelling and contractility by magnetic resonance imaging. , 2005, European heart journal.
[53] H. Dargie. Heart failure post-myocardial infarction: a review of the issues , 2005, Heart.
[54] M. Chiariello,et al. Late reopening of an occluded infarct related artery improves left ventricular function and long term clinical outcome , 2005, Heart.
[55] J. Daubert,et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.
[56] M. Briel,et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. , 2005, Archives of internal medicine.
[57] J. McMurray,et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. , 2005, Journal of the American College of Cardiology.
[58] Y. Kagaya,et al. Poor prognosis of Japanese patients with chronic heart failure following myocardial infarction--comparison with nonischemic cardiomyopathy. , 2005, Circulation journal : official journal of the Japanese Circulation Society.
[59] Douglas L Packer,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.
[60] I. Olkin,et al. Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. , 2004, American heart journal.
[61] A. Skene,et al. Impact of nicorandil in angina: subgroup analyses , 2004, Heart.
[62] G. Braunstein,et al. Meta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction , 2004, Annals of Internal Medicine.
[63] J. Schroeder,et al. Effects of Cardiac Resynchronization on Disease Progression in Patients With Left Ventricular Systolic Dysfunction, an Indication for an Implantable Cardioverter-Defibrillator, and Mildly Symptomatic Chronic Heart Failure , 2004, Circulation.
[64] J. Reiber,et al. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study. , 2004, International journal of cardiology.
[65] F. Fernández‐Avilés,et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial , 2004, The Lancet.
[66] K. Shimada,et al. Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study , 2004, Circulation.
[67] K. Swedberg,et al. [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.
[68] H. Ueshima,et al. [Weight-control intervention in overweight subjects at high risk of cardiovascular disease: a trial of a public health practical training program in a medical school]. , 2004, [Nihon koshu eisei zasshi] Japanese journal of public health.
[69] D. DeMets,et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.
[70] S. Ebrahim,et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. , 2004, The American journal of medicine.
[71] E. Gurfinkel,et al. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. , 2004, European heart journal.
[72] T. Takebayashi,et al. Stages of change for salt intake and urinary salt excretion: baseline results from the High-Risk and Population Strategy for Occupational Health Promotion (HIPOP-OHP) study. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.
[73] S. Hosoda,et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. , 2004, American heart journal.
[74] Carl J Pepine,et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.
[75] Peter C Austin,et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.
[76] Karl Swedberg,et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.
[77] E. Foster,et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. , 2003, Journal of the American College of Cardiology.
[78] S. Hosoda,et al. Effect of trapidil on cardiovascular events in patients with coronary artery disease (results from the Japan Multicenter Investigation for Cardiovascular Diseases-Mochida [JMIC-M]). , 2003, The American journal of cardiology.
[79] U. Zeymer,et al. Randomized Comparison of Percutaneous Transluminal Coronary Angioplasty and Medical Therapy in Stable Survivors of Acute Myocardial Infarction With Single Vessel Disease: A Study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte , 2003, Circulation.
[80] M. Pfeffer,et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.
[81] P. Elliott,et al. Higher blood pressure in middle-aged American adults with less education—role of multiple dietary factors: The INTERMAP Study , 2003, Journal of Human Hypertension.
[82] H. Ueshima,et al. Differences in cardiovascular disease risk factors between Japanese in Japan and Japanese-Americans in Hawaii: the INTERLIPID study , 2003, Journal of Human Hypertension.
[83] Markolf Hanefeld,et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.
[84] B. Pitt,et al. Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .
[85] N. Frasure-smith,et al. Depression and other psychological risks following myocardial infarction. , 2003, Archives of general psychiatry.
[86] R. Canby,et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. , 2003, JAMA.
[87] P. Armstrong,et al. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. , 2003, Annals of internal medicine.
[88] Peter Sleight,et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. , 2003, JAMA.
[89] D. Williamson,et al. Intentional Weight Loss and Death in Overweight and Obese U.S. Adults 35 Years of Age and Older , 2003, Annals of Internal Medicine.
[90] H. Ogawa,et al. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. , 2003, The American journal of cardiology.
[91] H. Crijns,et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. , 2002, The New England journal of medicine.
[92] E. Rimm,et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. , 2003, The New England journal of medicine.
[93] A L Waldo,et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.
[94] H. Arnesen,et al. Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.
[95] K. Dickstein,et al. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.
[96] R. Califf,et al. Sertraline treatment of major depression in patients with acute MI or unstable angina , 2002, European Neuropsychopharmacology.
[97] N. Hagiwara,et al. Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. , 2002, Circulation journal : official journal of the Japanese Circulation Society.
[98] J. Oss,et al. PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .
[99] V. Fuster,et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Circulation.
[100] D. Bush,et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. , 2001, The American journal of cardiology.
[101] H. Dargie,et al. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.
[102] J. Gore,et al. Outcomes and early revascularization for patients > or = 65 years of age with cardiogenic shock. , 2001, The American journal of cardiology.
[103] M. Biase,et al. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. , 2001, Journal of the American College of Cardiology.
[104] M. Oz,et al. Optimal timing of revascularization: transmural versus nontransmural acute myocardial infarction. , 2001, The Annals of thoracic surgery.
[105] J. Daubert,et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. , 2001, The New England journal of medicine.
[106] M. Goolsby,et al. Treating Tobacco Use and Dependence , 2008, Pediatrics.
[107] S. Connolly,et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. , 2000, European heart journal.
[108] H. Ueshima,et al. Effectiveness of smoking-cessation intervention in all of the smokers at a worksite in Japan. , 2000, Industrial health.
[109] A. Jacobs,et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction : A report from the shock trial Registry , 2000 .
[110] R. Cappato,et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). , 2000, Circulation.
[111] Bezafibrate Infarction Prevention study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.
[112] J. Hedner,et al. Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. , 2000, American journal of respiratory and critical care medicine.
[113] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[114] M Gent,et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. , 2000, Circulation.
[115] I. Piña,et al. AHA Science Advisory. Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association; Position paper endo , 2000, Circulation.
[116] Berndt Lüderitz,et al. Obstructive Sleep Apnea as a Risk Marker in Coronary Artery Disease , 2000, Cardiology.
[117] E. Prystowsky,et al. Implantable defibrillator event rates in patients with unexplained syncope and inducible sustained ventricular tachyarrhythmias: a comparison with patients known to have sustained ventricular tachycardia. , 1999, Journal of the American College of Cardiology.
[118] P. Lavie,et al. Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment. , 1999, Journal of the American College of Cardiology.
[119] S. Markowitz,et al. Long-term outcome of patients with unexplained syncope treated with an electrophysiologic-guided approach in the implantable cardioverter-defibrillator era. , 1999, Journal of the American College of Cardiology.
[120] Roberto Marchioli,et al. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .
[121] R. Holman,et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.
[122] Y. Tamura,et al. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. , 1999, The American journal of cardiology.
[123] J. Gurwitz,et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. , 1999, The New England journal of medicine.
[124] L. Bujanda,et al. Mortality and light to moderate alcohol consumption after myocardial infarction , 1999, The Lancet.
[125] M. Pfeffer,et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. , 1999, Journal of the American College of Cardiology.
[126] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[127] K. Gould,et al. Intensive lifestyle changes for reversal of coronary heart disease. , 1998, JAMA.
[128] P C Deedwania,et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. , 1998, Circulation.
[129] M. Kinoshita,et al. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. , 1998, Circulation.
[130] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[131] R. Collins,et al. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. , 1998, Circulation.
[132] P. Lavori,et al. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. , 1997, Circulation.
[133] C. Schuger,et al. Implantable Cardioverter Defibrillator Utilization Among Device Recipients Presenting Exclusively with Syncope or Near‐Syncope , 1997, Journal of cardiovascular electrophysiology.
[134] H. Arendrup,et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. , 1997, Circulation.
[135] G A Colditz,et al. A prospective study of passive smoking and coronary heart disease. , 1997, Circulation.
[136] A. Tamura,et al. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group. , 1997, The American journal of cardiology.
[137] S. Connolly,et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT , 1997, The Lancet.
[138] A. Camm,et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT , 1997, The Lancet.
[139] J. Manson,et al. Moderate Alcohol Consumption and Risk for Angina Pectoris or Myocardial Infarction in U.S. Male Physicians , 1997, Annals of Internal Medicine.
[140] P. J. Wang,et al. High incidence of appropriate implantable cardioverter-defibrillator therapy in patients with syncope of unknown etiology and inducible ventricular arrhythmias. , 1997, Journal of the American College of Cardiology.
[141] M. Dennis. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .
[142] J. Lubsen,et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. , 1996, Heart.
[143] K Steenland,et al. Environmental tobacco smoke and coronary heart disease in the American Cancer Society CPS-II cohort. , 1996, Circulation.
[144] G. Breithardt,et al. Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. , 1996, Circulation.
[145] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[146] M. Block,et al. Nonpharmacological therapy for malignant ventricular arrhythmias: implantable defibrillator trials. , 1996, Progress in cardiovascular diseases.
[147] H. Crijns,et al. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors. A randomized study. , 1996, Circulation.
[148] F. Messerli,et al. Nifedipine and mortality. Grave defects in the dossier. , 1995, Circulation.
[149] B. Psaty,et al. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.
[150] T. Raghunathan,et al. The risk of myocardial infarction associated with antihypertensive drug therapies. , 1995, JAMA.
[151] Raymond C. Schneider,et al. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.
[152] M. Fujishima,et al. The impact of alcohol and hypertension on stroke incidence in a general Japanese population. The Hisayama Study. , 1995, Stroke.
[153] M. Hull,et al. AICD™ Automatic Cardioverier Defibrillator Clinical Update: 14 Years Experience in Over 34,000 Patients , 1995, Pacing and clinical electrophysiology : PACE.
[154] J. Manson,et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. , 1994, Archives of internal medicine.
[155] S. Glasser,et al. Phenomenon of nitrate tolerance. , 1994, American heart journal.
[156] A. G. Shaper,et al. Alcohol and coronary heart disease: a perspective from the British Regional Heart Study. , 1994, International journal of epidemiology.
[157] C. Dennis,et al. A Case-Management System for Coronary Risk Factor Modification after Acute Myocardial Infarction , 1994, Annals of Internal Medicine.
[158] K. Kuck,et al. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). , 1994, American heart journal.
[159] K. Swedberg,et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.
[160] M. Gheorghiade,et al. WITHDRAWAL OF DIGOXIN FROM PATIENTS WITH CHRONIC HEART FAILURE TREATED WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS , 2010 .
[161] N. Frasure-smith,et al. Depression following myocardial infarction. Impact on 6-month survival. , 1993, JAMA.
[162] C. Furberg,et al. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. , 1993, JAMA.
[163] B. Uretsky,et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. , 1993, Journal of the American College of Cardiology.
[164] J. Mason. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. , 1993, The New England journal of medicine.
[165] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[166] R. Kronmal,et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1992, Journal of the American College of Cardiology.
[167] G. Guiraudon,et al. Reduction in defibrillator shocks with an implantable device combining antitachycardia pacing and shock therapy. , 1991, Journal of the American College of Cardiology.
[168] H L Greene,et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.
[169] F. Marchlinski,et al. Value of ventricular electrogram recordings in the diagnosis of arrhythmias precipitating electrical device shock therapy. , 1991, Journal of the American College of Cardiology.
[170] P. Tchou,et al. Survival in Patients with Depressed Left Ventricular Function Treated by Implantable Cardioverter Defibrillator , 1991, Pacing and clinical electrophysiology : PACE.
[171] K. Ishikawa,et al. Effect of dipyridamole at the usual oral dose on exercise-induced myocardial ischemia in stable angina pectoris. , 1990, The American journal of cardiology.
[172] S. Shapiro,et al. Decline in the risk of myocardial infarction among women who stop smoking. , 1990, The New England journal of medicine.
[173] R. Gorlin,et al. The nature and course of depression following myocardial infarction. , 1989, Archives of internal medicine.
[174] E. Mellits,et al. Prophylactic antiarrhythmic therapy of high-risk survivors of myocardial infarction: lower mortality at 1 month but not at 1 year. , 1987, Circulation.
[175] R. Byington,et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. , 1986, Circulation.
[176] S. Shapiro,et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. , 1985, The New England journal of medicine.
[177] Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). , 2014, Circulation journal : official journal of the Japanese Circulation Society.
[178] M. Özkaya,et al. Action to Control Cardiovascular Risk in Diabetes , 2013 .
[179] J. Stockman. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials , 2011 .
[180] G. Moneta. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2010 .
[181] T. Sakamoto,et al. [Multicenter study for aggressive lipid-lowering strategy by HMG-CoA reductase inhibitors]. , 2009, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.
[182] Claudia Stöllberger,et al. Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2009, Heart rhythm.
[183] 奥田 奈賀子. Relation of long chain n-3 polyunsaturated fatty acid intake to serum high density lipoprotein cholesterol among Japanese men in Japan and Japanese-American men in Hawaii : the INTERLIPID study , 2009 .
[184] J. Marin-Neto. Telmisartan, ramipril, or both in patients at high risk for vascular events , 2008 .
[185] A. Rabinstein. Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial , 2008 .
[186] B. Gersh. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials , 2008 .
[187] Hiroshi Takahashi,et al. Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. , 2007, Clinical therapeutics.
[188] S. Sasayama,et al. Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-stokes respiration. , 2006, Circulation journal : official journal of the Japanese Circulation Society.
[189] M. Rich,et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. , 2006, European heart journal.
[190] M. Hanefeld,et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. , 2004, European heart journal.
[191] Eric J Topol,et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. , 2004, JAMA.
[192] K. Swedberg,et al. Expert consensus document on beta-adrenergic receptor blockers. , 2004, European heart journal.
[193] B. Pitt,et al. EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .
[194] Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). , 2002, Circulation journal : official journal of the Japanese Circulation Society.
[195] V. Fuster,et al. Results of Expert Meetings: Obesity and Cardiovascular Disease. Obesity as a risk factor in coronary artery disease. , 2001, American heart journal.
[196] Arma,et al. EFFECTS OF MULTISITE BIVENTRICULAR PACING IN PATIENTS WITH HEART FAILURE AND INTRAVENTRICULAR CONDUCTION DELAY , 2001 .
[197] M. C. Crim,et al. High-intensity strength training of patients enrolled in an outpatient cardiac rehabilitation program. , 1999, Journal of cardiopulmonary rehabilitation.
[198] R. Katori,et al. Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. , 1997, Japanese circulation journal.
[199] I. Nakada. Prediction of exercise capacity in the chronic phase of myocardial infarction by non-supervised home exercise therapy : Consideration of physical and psychosocial factors at discharge , 1994 .
[201] H. Greene. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators. , 1993, The American journal of cardiology.
[202] M. Gheorghiade,et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. , 1993, The New England journal of medicine.
[203] Robert Lemery,et al. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. , 1992, The New England journal of medicine.
[204] Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. , 1981, The New England journal of medicine.